JPRN-jRCT2080220460未知2 期
Multi-Center, Parallel-Group, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety and Efficacy of Oral Lubiprostone in Patients with Chronic Idiopathic Constipation
Sucampo Pharma, Ltd.0 个研究点开始时间: 2007年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Adult chronic idiopathic constipation
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Multi-centre, parallel group, double-blind, placebo controlled study of the efficacy and tolerability of TONABERSAT in prophylaxis of migraine headacheMigraine with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2).EUCTR2005-004835-23-DKMinster Pharmaceuticals Ltd128
进行中（未招募）
不适用
Multi-centre, parallel group, double-blind, placebo controlled study of the efficacy and tolerability of TONABERSAT in prophylaxis of migraine headacheMigraine with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2).EUCTR2005-004835-23-GBMinster Pharmaceuticals Ltd128
进行中（未招募）
不适用
Multi-centre, parallel group, double-blind, placebo controlled study of the efficacy and tolerability of TONABERSAT in prophylaxis of migraine headacheMigraine with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders (Edition 2).EUCTR2005-004835-23-HUMinster Pharmaceuticals Ltd128
已完成
3 期
Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment.Parkinson's diseaseparkinsonismNL-OMON41299Britannia Pharmaceuticals Ltd20
进行中（未招募）
1 期
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004431-24-PLJanssen-Cilag International NV212